EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 285 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... March 8, 2021 Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... February 3, 2023 Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... September 26, 2019 ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical... October 8, 2025 Load more HOT NEWS Scientists developing urine and blood tests to detect brain tumours News digest – Genetic links to male breast cancer, bowel cancer... Cannabis, cannabinoids and cancer – the evidence so far Shannen Doherty Reveals She Has Stage IV Breast Cancer
